PATIENTS will continue to have access to a PBS-subsidised dipyridamole and aspirin combination, with the discontinued Asasantin SR able to be substituted with Diasp SR from Arrotex.
Arrotex said it was taking steps to ensure the Australian market had greater supply of Diasp SR following the discontinuation of Asasantin SR, with the company saying supply would build over time and anticipating stock will become locally available in the coming weeks.
The dipyridamole and aspirin combination is used to prevent the recurrence of ischaemic stroke or transient cerebral ischaemic events.
"As the largest supplier to the PBS by volume, Arrotex is committed to ensuring Australian patients have ongoing access to their medicines," the firm said.
Diasp SR has been 'a' flagged by the Pharmaceutical Benefits Scheme as bioequivalent and interchangeable with Asasantin.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Sep 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Sep 20
